BET Inhibitor Trotabresib in Heavily Pretreated Patients With Solid Tumors and Diffuse Large B-Cell Lymphomas
Recommended
BET Inhibitor Trotabresib in Heavily Pretreated Patients With Solid Tumors and Diffuse Large B-Cell Lymphomas
Researchers report long-term follow-up results of an open label, phase 1 study examining the use of trotabresib in patients with solid tumors and relapsed/refractory diffuse large B-cell lymphoma for safety and tolerability. Study authors concluded that, “these results support further investigation of trotabresib in combination with other anticancer agents.”
Access the full article to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->